{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:15:15Z","timestamp":1790388915919,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.lpm.2025.104268","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T16:14:22Z","timestamp":1737216862000},"page":"104268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Updates on mechanisms of disease progression in precursor myeloma: Monoclonal gammopathy of undermined significance and smoldering myeloma"],"prefix":"10.1016","volume":"54","author":[{"given":"Cynthia","family":"Saade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2025.104268_bib0001","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2025.104268_bib0002","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.lpm.2025.104268_bib0003","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2025.104268_bib0004","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2025.104268_bib0005","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","article-title":"Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana","volume":"82","author":"Landgren","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.lpm.2025.104268_bib0006","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa0708704","article-title":"Familial myeloma","volume":"359","author":"Lynch","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2025.104268_bib0007","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood-2008-12-191676","article-title":"Risk of plasma-cell and lymphoproliferative disorders among 14,621 first-degree relatives of 4,458 patients with monoclonal gammopathy of undetermined significance (MGUS) in Sweden","volume":"114","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2025.104268_bib0008","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2008-12-192575","article-title":"Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance","volume":"114","author":"Vachon","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lpm.2025.104268_bib0009","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.3324\/haematol.2023.283191","article-title":"Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study","volume":"108","author":"Sigurbergsd\u00f3ttir","year":"2023","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.lpm.2025.104268_bib0010","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","article-title":"Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study","volume":"9","author":"El-Khoury","year":"2022","journal-title":"Lancet Haematol"},{"issue":"supplement 1","key":"10.1016\/j.lpm.2025.104268_bib0011","doi-asserted-by":"crossref","first-page":"7228","DOI":"10.1182\/blood-2022-167268","article-title":"Prevalence of monoclonal gammopathies detected by mass spectrometry and their risk factors among black Africans in South Africain","volume":"140","author":"Lee","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2025.104268_bib0012","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal immunoglobulin against lysolipids in the origin of myeloma","volume":"374","author":"Nair","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2025.104268_bib0013","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2025.104268_bib0014","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2025.104268_bib0015","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2025.104268_bib0016","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.lpm.2025.104268_bib0017","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","author":"Cowan","year":"2023","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.lpm.2025.104268_bib0018","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1038\/leu.2016.123","article-title":"Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma","volume":"30","author":"Gonzalez-Calle","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.lpm.2025.104268_bib0019","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.lpm.2025.104268_bib0020","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2025.104268_bib0021","first-page":"393","article-title":"MYC translocations identified by sequencing panel in smoldering multiple myeloma strongly predict for rapid progression to multiple myeloma","volume":"130","author":"Keane","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2025.104268_bib0022","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2014.75","article-title":"Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma","volume":"28","author":"Merz","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.lpm.2025.104268_bib0023","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.lpm.2025.104268_bib0024","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2021-146535","article-title":"Circulating tumor cells (CTCs) in smoldering and active multiple myeloma (MM): mechanism of egression, clinical significance and therapeutic endpoints","volume":"138","author":"Garc\u00e9s","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2025.104268_bib0025","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.lpm.2025.104268_bib0026","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.lpm.2025.104268_bib0027","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2017.345","article-title":"Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines","volume":"32","author":"Maura","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.lpm.2025.104268_bib0028","doi-asserted-by":"crossref","first-page":"7122","DOI":"10.1038\/s41598-019-43575-y","article-title":"Endogenous APOBEC3B overexpression constitutively generates DNA substitutions and deletions in myeloma cells","volume":"9","author":"Yamazaki","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.lpm.2025.104268_bib0029","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/2159-8290.CD-22-0482","article-title":"MinimuMM-seq: genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology","volume":"13","author":"Dutta","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.lpm.2025.104268_bib0030","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma","volume":"117","author":"Walker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2025.104268_bib0031","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.4049\/jimmunol.1202493","article-title":"Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis","volume":"190","author":"Heuck","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.lpm.2025.104268_bib0032","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1101\/gr.180240.114","article-title":"Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers","volume":"25","author":"Agirre","year":"2015","journal-title":"Genome Res"},{"key":"10.1016\/j.lpm.2025.104268_bib0033","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s43018-020-00131-2","article-title":"The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome","volume":"1","author":"Duran-Ferrer","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.lpm.2025.104268_bib0034","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood-2017-09-808063","article-title":"Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma","volume":"131","author":"Jin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2025.104268_bib0035","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1101\/gr.265520.120","article-title":"Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma","volume":"30","author":"Ordonez","year":"2020","journal-title":"Genome Res"},{"key":"10.1016\/j.lpm.2025.104268_bib0036","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1038\/s41467-021-25704-2","article-title":"Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma","volume":"12","author":"Alvarez-Benayas","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.lpm.2025.104268_bib0037","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1158\/1078-0432.CCR-20-2931","article-title":"Chromatin accessibility identifies regulatory elements predictive of gene expression and disease outcome in multiple myeloma","volume":"27","author":"Barwick","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lpm.2025.104268_bib0038","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.4202","article-title":"Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice","volume":"22","author":"Das","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.lpm.2025.104268_bib0039","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nature Cancer"},{"key":"10.1016\/j.lpm.2025.104268_bib0040","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ccell.2022.10.017","article-title":"Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma","volume":"40","author":"Sklavenitis-Pistofidis R","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lpm.2025.104268_bib0041","doi-asserted-by":"crossref","first-page":"e127807","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"511","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.lpm.2025.104268_bib0042","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2025.104268_bib0043","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lpm.2025.104268_bib0044","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","article-title":"Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study","volume":"174","author":"Mateos","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lpm.2025.104268_bib0045","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2025.104268_bib0046","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2023-177954","article-title":"Immuno-PRISM: a randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma","volume":"142","author":"Nadeem","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2025.104268_bib0047","unstructured":"Nadeem O. in Intercepting blood cancers (IBC). Madrid, Spain (Intercepting Blood Cancers (IBC) Meeting)"},{"key":"10.1016\/j.lpm.2025.104268_bib0048","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/blood-2021-147704","article-title":"Iberdomide (IBER) in combination with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the dose-expansion phase of the CC-220-MM-001 trial","volume":"138","author":"Lonial","year":"2021","journal-title":"Blood"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498225000016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498225000016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T23:46:50Z","timestamp":1741045610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498225000016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0755498225000016"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2025.104268","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on mechanisms of disease progression in precursor myeloma: Monoclonal gammopathy of undermined significance and smoldering myeloma","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2025.104268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104268"}}